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This work was presented in part at the Keystone Symposia on HIV Vaccines 51 (X5) conference joint with the golden anniversary of B cell discovery meeting in Banff 52 Springs, Banff, Alberta Canada, poster number X5 2023, 22-27th Mortality from HIV associated cryptococcal meningitis co-infection remains 88 abnormally high despite the use of optimal antifungal therapy and highly active 89 antiretroviral therapy to treat HIV-1 and cryptococcal meningitis co-infected patients. 90
However, it is not clear what contributes to the excess mortality after onset of 91 cryptococcosis. We found an association of high percent expression of programmed 92 death-1 (PD-1) receptor on plasmablasts/plasma cells population with host survival. We 93 also found high expression of B cell activated cells and more mature B cell population in 94 CSF compared to blood and this B cell dominant population in CSF of cryptococcosis 95 patients expressed more PD-1. Together, these data in CSF and blood of cryptococcosis 96 patients may informs further mechanistic studies of cryptococcus and host interaction to 97 advance our understating of the possible pathways that may be targeted to influence 98 pathogen control and host immune regulation to improve host survival. 99
Introduction 101
Meningitis caused by the encapsulated fungus Cryptococcus neoformans is a 102 leading cause of death among HIV-infected immune suppressed patients in sub-Saharan 103 Africa, accounting for 15% of their deaths worldwide (1) . Despite frequent exposure to the 104 yeast in the environment, cryptococcal infection is very rare in healthy individuals. 105
Immune status is a critical determinant of risk for fatal cryptococcosis. Type 1 helper T 106 cells may contain primary infection in the lungs as a cornerstone of protection among 107 healthy person (with ≈800-1200 circulating CD4+ T cells/µL) (2) . However, most HIV-108 infected patients present with cryptococcal meningitis at a very advanced state of 109 immunosuppression with CD4+ T cell counts <50 cells/µL (1) . 110 naïve T cell activation, generating and maintaining serological memory, and regulating 112 immune responses in health and in disease (3, 4) . In animal models, B cells produce 113 antibodies against the cryptococcal polysaccharide capsule and other fungal antigens 114 (5, 6) that may attenuate infection and mediate fungal clearance (7) . Specific antibodies 115 may support opsonization and killing of the organism by phagocytes (8, 9) , neutralization 116 of fungal virulence factors (10) or direct antibody-mediated toxicity and interference with 117 fungal metabolism (7) . B cells can produce either pro-inflammatory (e.g., IL-6, TNF-α and 118 IFN-γ) (11) or anti-inflammatory cytokines (e.g., IL-10). IL-10-producing regulatory B cells, 119
including plasma cells, modulate the activity of other immune cells in the local 120 environment (4), as may B cells expressing surface immunomodulatory molecules such 121 as PD-1 (12, 13) . 122
The contribution of pathogen-specific antifungal responses can be compromised 123 during HIV-1 infection by polyclonal B cell activation and attenuated humoral responses 124 to primary and recall antigens (14) . Both Cryptococcus and HIV may have profound 125
Circulating CD4+ T cell numbers were low in all HIV-infected subjects tested. CSF protein 136 levels were similar among those with cryptococcal and non-cryptococcal meningitis. 137
Although the Glasgow coma score was abnormal in only a quarter of subjects with 138 cryptococcosis (<15 points), the 28-day mortality was high. 139
Among all HIV-infected subjects with known outcomes, 42.9% (15/35) B cell activation was significantly higher in both HIV-infected groups than among 157 healthy controls in blood (medians, 55% and 53% vs. 7%, respectively, p<0.03) and 158 higher yet in CSF, 68% and 77% ( Figure 2B ). Among cryptococcosis subjects, B cell
B cell subsets and activation in blood and CSF 163
Circulating B cells in blood showed distinct differences in subset distribution and 164 activation. Naïve B cells predominated in blood in all groups ( Figure 3A ). Memory cells in 165 blood were significantly lower among both HIV-infected groups compared with healthy 166 control subjects. Tissue-like memory cells were over five-fold higher with HIV infection 167 than in healthy controls. Plasmablasts/plasma cells, although a minority population in 168 blood, were overrepresented with HIV infection ( Figure 3A) . 169
In the CSF, B cells showed a more differentiated phenotype with naïve cells 170 representing only about a quarter of cells compared with the majority in blood in all groups 171 ( Figure 3A ); these proportions correlated in the two compartments ( Figure 3B ). Memory 172 cells were also prominent in the CSF, accounting for up to half of B cells, and also 173 correlated with those in blood ( Figure 3C ), suggesting trafficking between the two 174 compartments. Plasmablasts/plasma cells frequencies in CSF greatly exceeded those in 175 blood in HIV-infected subjects with (medians, 13% vs. 0.7%; p<0.001) and without 176 (medians, 9% vs. 1%; p=0.008) cryptococcosis ( Figure 3A) . 177
In addition to subset differences between circulating B cells, patients with HIV 178 demonstrated significantly higher levels of activation in both naïve and memory cells 179 compared with healthy controls ( Figure 3D ). Activation was greater yet in B cells in the 180 CSF, particularly among naïve cells, as well as among memory cells. These data indicate 181 that B cells that traffic and localize to the CSF may be activated by infection at that site. NKT cells and other myeloid derived cells (22) . PD-1 was expressed on a minority of 193 circulating B cells, but significantly more commonly on B cells in the CSF ( Figure 4A ). on 194 CD19-lymphocytes, (majority T cells), PD-1 though most prominent in this cell population 195 was more frequent in CSF than blood ( Figure 4A ). On the CD19-monocytes, was more 196 frequently expressed on CSF of cryptococcosis patient than blood ( Figure 4A ). In blood, 197 PD-1 expression was increased on more mature and on activated B cells, a pattern most 198 directly applicable to healthy control subjects and those with cryptococcosis ( Figure 4B ). 199
Most striking was the prominent high frequency of PD-1 on circulating CD27+ activated 200 memory, on tissue-like memory and on plasmablasts/plasma cells in healthy controls and 201 in the cryptococcosis co-infected group ( Figure 4B ). 202
Among other subsets, PD-1 was more commonly expressed on activated naive 203 and CD27+ B cells from blood of healthy control subjects than of HIV-infected adults 204 ( Figure 4B and Supplementary Table S3 ). Among circulating B cells from adults with HIV 205 infection, PD-1 was more prevalent on activated CD27+ memory activated and on Tissue-206 like memory, but not resting CD27+ memory B cells in those with Cryptococcus vs. non-207 cryptococcal meningitis. 208
As in blood, PD-1 in CSF was identified most frequently on PB/PC. These values 209 were significantly associated in the two compartments among cryptococcosis subjects 210 ( Figure 4C ). Thus, the preferential display of PD-1 on activated and differentiated memory 211 B cells in the healthy controls and in those with cryptococcosis invokes the possibility of 212 a regulatory role of this molecule on B cells in cryptococcal infection. 213
214

PD-1+ expression on plasmablasts/plasma cells correlates with mortality among 215 cryptococcal meningitis subjects 216
As noted above, overall mortality at 18 weeks was high in those with cryptococcal 217 meningitis (18/30; 60%). Among the various B cell subsets, only PD-1+ expression on 218 circulating plasmablasts/plasma cells was significantly associated with survival (also 219 overall B cell activation by univariate but not multivariate analysis). Of the 10 subjects 220 who died by 28 days after diagnosis with cryptococcosis, PD-1 was identified on a median 221 of 7% of circulating plasmablasts/plasma cells. In sharp contrast, PD-1 was expressed by 222 a median of 46% of these cells among 20 survivors ( Figure 5B ). Thus, low PD-1 223 expression was associated with early mortality and high PD-1 expression with survival. 224
Using PD-1+ plasmablasts/plasma cells as a continuous variable, every 5 units 225 increase in PD-1+ expression on these cells was associated with 17% less chance of 226 death in the acute setting by 28 days when most mortality occurred (HR (95% CI) = 0.83 227 (0.71, 0.98); p=0.02). This association of PD-1 on plasmablast/plasma cells at 228 presentation was no longer significant with overall mortality at 140 days (18 weeks) (HR 229 (95% CI) = 0.93 (0.84-1.02); p=0.13). In further exploration, using a cutoff point of 20% 230
PD-1 plasmablasts/plasma cells expression, subjects with the PD-1 values ≤ 20% had 231
had an increased risk of death (log rank p-value = 0.01; Figure 5C ). Those with PD-1 232 values < 20% had a 7-fold increased risk of 28-day mortality compared to those with PD-1 > 20% (HR (95% CI) = 7.38 (1.69-34.36); p=0.01). While intriguing, the confidence 234 interval is significant but wide, the p value is not very small, so this cutoff value is 235 exploratory. By univariant analysis, only circulating B cell activation independently 236 correlated with death (p=0.03); but not other reported risks for mortality (age, gender, 237
Glasgow coma score, CSF protein, CSF white cell counts, or CSF fungal quantitative 238 culture) (16, 23) . PD-1 expression on circulating B cells was associated with B cell 239 activation in blood ( Figure 5D ). Whether these observations represent a plausible the two meningitis groups). Akin to persons with multiple sclerosis (37,38), short-lived 280 CSF plasmablasts were also reported to be increased in adults with HIV infection, 281
particularly early in their course (39) . That B cells and plasmablast frequencies in the CSF 282 correlated with HIV RNA in the CSF and decreased with antiretroviral therapy in that study implicated the virus as a stimulus for the presence of these cells. B cells and short-lived 284 plasma blasts were also increased with neurosyphilis and declined with therapy (40) , 285
highlighting that secondary infections can also elicit these cells. We could not distinguish 286 between the more prominent plasmablasts and infrequent plasma cells described with 287 our markers, but the increased frequency of B cells of memory and plasmablast/plasma 288 cell with meningitis are consistent with the CNS responses to neurosyphilis, viral 289 meningitis and in multiple sclerosis (37-42). Whether ectopic germinal centers are 290 present in the brain with cryptococcal meningitis, which has a prominent component in 291 the brain parenchyma, as were identified with neurosyphilis (40) was increased on activated B cells, particularly CD27+ and tissue-like memory cells, as 307 reported by others (43, 45) . Indeed, microbial antigens, modeled by toll-like receptor-9 to its effects on T cells, PD-1 on B cells can inhibit B cell activation, suppress B cell 310 proliferation and impair B cell inflammatory cytokine responses (12, 13, 45, 47) . 311
Although less prominent on human B cells , PD-1 has been described at high levels 312
among SIV-infected macaques in association with loss of memory B cells and fatal 313
intestinal infection (48) . The prominence of PD-1 on B cells in our patients with 314 cryptococcal meningitis and the associated early and high mortality associated with its 315 expression on plasma cells are consistent with these results in primates who also died 316 with secondary infections. Blockade of PD-1 in the macaques augmented SIV-specific 317 antibodies and improved survival. Thus, PD-1 on B cells may limit the antibody-producing 318 effector function of B cells directly, and loss of innate-like IgM+ CD27+ memory B cells 319 population that produces natural IgM antibodies is associated with risk of cryptococcosis 320 among HIV infected individuals (49, 50) . PD-1 on B cells can also limit the effector activity 321 of neighboring CD4+ and CD8+ T cells (14) cultures (19) . The non-cryptococcal meningitis subjects where confirmed with tuberculosis and rifampicin gene xpert, 16S rRNA, and by quantitative fungal and 359 bacterial culture as previously described in this HIV meningitis cohort (17) . Of the non-360 cryptococcal meningitis co-infected subjects, 4 had Mycobacterium tuberculosis 361 meningitis, 1 had neurosyphilis, toxoplasmosis and Mycobacterium tuberculosis co-362 infections while, 7 were without a known HIV co-infecting etiology. Whole blood, but not 363 CSF, was obtained from healthy control subjects with neither HIV nor cryptococcal 364 infection (n=10) from an HIV observational rural Ugandan cohort (20) . Subjects 365 prospectively provided informed written consent for the parent studies. Makerere 366 University Research Ethics Committee granted ethical approval for use of stored 367 specimens from previously consented adults. None of the subjects was on steroids, on 368 ART or on anti-fungal therapy prior to sample collection. 369
Sample Preparation 371
Peripheral blood mononuclear cells (blood) and CSF samples were collected 372 within 72 hours of meningitis diagnosis. Blood and CSF cells were isolated and 373 cryopreserved as previously described (21) in Roswell Park Memorial Institute enriched 374 medium (69%) supplemented with 20% fetal bovine serum, 10% dimethyl sulphoxide and 375 1% penicillin/streptomycin in vapor phase in liquid nitrogen until testing. Blood and CSF 376 cells were thawed, and cell viabilities and cell recoveries determined using an automated 377
Guava PCA instrument before antibody staining for flow cytometry. 378
After thawing, median cell viability was 91% (range, 75-98%) from the CSF and 379 98% (Range 95-100%) from frozen PBMC. Median cells recovery was 1. Table 1, as described earlier (14, 51) . Gates indicated for PD-1, CD21 and CD38 were determined using fluorescence minus one cut-off [not shown], used to define subset expression, activation and PD-1 expression. 
Figure 2. B cells Frequency and Activation in blood and in cerebrospinal fluid
